Nasdaq:CYRX
Cryoport, Inc.
A premier global supplier of cryogenic logistics infrastructure enabling the safe transport and storage of advanced biologics for life sciences companies.
Key Metrics
Investment Thesis
Bull Case
Investors may view CYRX as a strategic play on the booming biologics market, where demand for specialized cryogenic storage is expected to grow significantly. The company's established global footprint and high switching costs associated with its proprietary containers provide a defensible position against new entrants. Potential stabilization in net losses could signal a turning point if operational efficiencies are realized without compromising growth investments.
Bear Case
The widening net loss trend from -$37.3M in 2022 to -$114.8M in 2024 raises concerns about the sustainability of current burn rates and path to profitability. High levels of accumulated other comprehensive income losses and a massive retained earnings deficit suggest significant historical financial strain that requires careful monitoring. Declining revenue from $237.3M in 2022 to $228.4M in 2024 may indicate market saturation or pricing pressure in an already competitive industry.
About Cryoport, Inc.
Cryoport, Inc. (CYRX) is a leading global provider of cryogenic storage and logistics solutions for the life sciences industry, serving pharmaceutical and biotechnology markets worldwide. The company specializes in manufacturing specialized containers, tankers, and providing temperature-controlled transportation services to ensure the integrity of sensitive biological products during shipping and storage.
Analysis
Management Discussion
Financial performance in 2024 reflects continued strategic investment, with cash flow from investing surging to $176.8M while operating cash flows remained negative at -$16.3M due to aggressive expansion efforts. Despite significant R&D spending of $17.7M and share-based compensation of $19.7M, the company reported a gross profit of $99.6M against total revenue of $228.4M, indicating healthy margins on core logistics services even as net losses widened.
Industry Overview
The cryogenic logistics industry is experiencing robust growth driven by the rapid expansion of mRNA vaccines, gene therapies, and other complex biologics that require ultra-low temperature transport. Market leaders are consolidating to capture economies of scale as smaller players struggle with the high capital requirements for specialized infrastructure. Regulatory scrutiny regarding cold chain integrity is increasing, favoring established companies with proven safety records.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $237.3M | $233.3M | $228.4M |
| Cost of Revenue | $133.4M | $133.9M | $128.8M |
| Gross Profit | $103.9M | $99.3M | $99.6M |
| Operating Expenses | $135.8M | $214.5M | $230.5M |
| Operating Income | $-31.9M | $-115.2M | $-130.9M |
| R&D | $15.7M | $18.0M | $17.7M |
| G&A | $120.1M | $146.9M | $149.0M |
| Stock-Based Comp | $20.1M | $22.8M | $19.7M |
| D&A | $22.8M | $27.5M | $30.8M |
| Depreciation | $7.7M | $11.2M | $13.6M |
| Amortization | $15.1M | $16.3M | $17.0M |
| Other OpEx | $0 | $49.6M | $63.8M |
| Non-Operating Income | $-3.2M | $15.8M | $17.4M |
| Interest Expense | $6.1M | $5.5M | — |
| Pre-Tax Income | $-35.1M | $-99.3M | $-113.5M |
| Income Tax | $2.2M | $239.0K | $1.3M |
| Continuing Ops | $-37.3M | $-99.6M | $-114.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-37.3M | $-99.6M | $-114.8M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-37.3M | $-99.6M | $-114.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $604.2M | $535.1M | $341.6M |
| Cash & Equivalents | $36.6M | $46.3M | $45.3M |
| Marketable Securities | $486.7M | $410.4M | $216.5M |
| Accounts Receivable | $43.9M | $42.1M | $45.8M |
| Inventory | $27.7M | $26.2M | $22.5M |
| Prepaid Expenses | $9.3M | $10.1M | $11.6M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $434.6M | $422.6M | $361.9M |
| PP&E (Net) | $63.6M | $84.9M | $88.8M |
| Goodwill | $151.1M | $108.4M | $51.7M |
| Operating Leases | $26.9M | $32.7M | $47.2M |
| Other LT Assets | $193.0M | $196.7M | $174.2M |
| Total Assets | $1.04B | $957.7M | $703.5M |
| Current Liabilities | $40.9M | $45.6M | $64.6M |
| Current Leases | $3.7M | $5.4M | $5.4M |
| Deferred Revenue | $439.0K | $1.3M | $1.1M |
| Other Current Liab | $36.7M | $38.9M | $58.0M |
| Long-Term Liabilities | $442.1M | $423.1M | $237.0M |
| LT Operating Leases | $24.7M | $29.4M | $44.1M |
| Other LT Liab | $417.3M | $393.8M | $193.0M |
| Total Liabilities | $482.9M | $468.7M | $301.6M |
| Shareholders' Equity | $555.8M | $489.0M | $401.9M |
| Paid-In Capital | — | $1.13B | $1.15B |
| Retained Earnings | $-542.8M | $-642.4M | $-757.2M |
| AOCI | — | $-26.1M | $-20.9M |
| Total L&E | $1.04B | $957.7M | $703.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-37.3M | $-99.6M | $-114.8M |
| Non-Cash Adjustments | $24.1M | $106.9M | $97.7M |
| Working Capital Changes | $11.4M | $-8.1M | $746.0K |
| Cash from Operations | $-1.9M | $-757.0K | $-16.3M |
| Capital Expenditures | $22.1M | $38.8M | $17.3M |
| Cash from Investing | $-59.7M | $36.0M | $176.8M |
| Share Buybacks | $38.0M | — | — |
| Cash from Financing | $-39.2M | $-23.8M | $-161.5M |
| FX Effect | $-1.8M | $-1.7M | $-18.0K |
| Net Change in Cash | $-102.5M | $9.8M | $-1.1M |
| Beginning Cash | $139.1M | $36.6M | $46.3M |
| Ending Cash | $36.6M | $46.3M | $45.3M |
Frequently Asked Questions
How does Cryoport, Inc. make money?
The company's revenue is primarily driven by its Cryoport Container business, which manufactures specialized ISO tanks and containers for pharmaceutical transport. A significant portion of revenue also comes from the Cryoport Tanker business, providing dedicated cryogenic logistics services to major biopharma clients. Additionally, the company generates income through its Cryoport Cold Chain Services, offering temperature-controlled warehousing and distribution solutions.
What are the main risks for CYRX?
The company faces substantial cash burn risks, evidenced by a net loss of $114.8M in 2024 and significant accumulated retained earnings deficits. Heavy reliance on large-scale capital expenditures for facility expansion exposes the firm to potential overcapacity or funding liquidity issues if growth slows. Regulatory changes in international trade or transportation safety could disrupt logistics operations and impact revenue stability.
What is CYRX's competitive advantage?
Cryoport possesses a dominant global market share in specialized cryogenic storage infrastructure, creating high barriers to entry for competitors. The company benefits from strong, long-term contractual relationships with major biopharma players that require complex, temperature-sensitive supply chains. Its extensive network of cold chain facilities and proprietary container technology ensures reliability and scalability that smaller rivals cannot match.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.